Transforming lives in immune mediated disease
Transforming lives in immune mediated disease
Quell Therapeutics is a clinical-stage company, fuelled by curiosity and discovery, on a mission to make life better for those battling severe immune and inflammatory disease
Discover our industry-leading platform and technology
WE ARE PIONEERS
At Quell, we are reimagining the treatment of severe immune disorders.
Our goal is to leverage the unique potential of Tregs to reinstate immune balance, bringing long-lasting control to patients with severe immune diseases.
The Problem
When immune tolerance is lost
Each day, the immune system delicately navigates the balance between self-tolerance and protection against external threats.
When this equilibrium is broken, it can lead to autoimmunity, chronic inflammation, or, in the case of organ transplantation, graft rejection.
Within this intricate interplay, Tregs serve as the pivotal regulators of tolerance - dampening immune responses and applying the brakes to prevent autoreactivity, inflammation and subsequent tissue damage.
Through engineering a patient's own Tregs, Quell aims to develop treatments with the potential to transform and to save lives.
Discover our Science
Our Platform
Delivering the most functionally stable and potent targeted Tregs
with the optimal cell product at our core and a suite of innovative technologies to ensure continued trailblazing progress
Core Platform
Stability
Phenotype-Lock™ Tregs
Quell leverages its cutting-edge Phenotype Lock technology to revolutionize the Treg cell therapy approach. By transducing the cells with the Treg master transcription factor, FOXP3, we ensure sustained and robust FOXP3 expression at all times. This innovative approach locks Tregs in a highly stable and suppressive state, empowering them to effectively modulate immune responses and withstand inflammatory challenge. Our ground-breaking technology amplifies the therapeutic potential of Tregs, setting a new standard in immune regulation and tolerance induction.
Our Platform
Delivering the most functionally stable and potent targeted Tregs
with the optimal cell product at our core and a suite of innovative technologies to ensure continued trailblazing progress
Core Platform
Core Platform
Stability
Phenotype-Lock™ Tregs
Quell leverages its cutting-edge Phenotype Lock technology to revolutionize the Treg cell therapy approach. By transducing the cells with the Treg master transcription factor, FOXP3, we ensure sustained and robust FOXP3 expression at all times. This innovative approach locks Tregs in a highly stable and suppressive state, empowering them to effectively modulate immune responses and withstand inflammatory challenge. Our ground-breaking technology amplifies the therapeutic potential of Tregs, setting a new standard in immune regulation and tolerance induction.
Team & Culture
Empowered by our people
Empowered by our people
At Quell we present a calling for visionaries looking to shape the future of healthcare
